Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis

Neoplasia

Volumn 11, Issue 1, 2009, Pages 66-76

  Wu, Zhong ^a   Cho, HyungJun ^b   Hampton, Garret M ^c   Theodorescu, Dan ^a,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Korea University   (South Korea)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN 6; CYCLIN E; CYCLIN E2; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE G1 PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE CONTROL; GENE MUTATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSCRIPTOMICS; UPREGULATION; WILD TYPE;

EID: 58249122862     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81048     Document Type: Article

References (41)

1. Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, and van Golen KL (2008). Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 10, 797-803.
2. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, Cher ML, et al. (2008). C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 10, 996-1003.
3. Ali IU, Schriml LM, and Dean M (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91, 1922-1932.
4. El Sheikh SS, Romanska HM, Abel P, Domin J, and Lalani el-N (2008). Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer-a pilot study. Neoplasia 10, 949-953.
5. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, and Bova GS (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58, 204-209.
6. Abate-Shen C and Shen MM (2000). Molecular genetics of prostate cancer. Genes Dev 14, 2410-2434.
7. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, and Sellers WR (1999). Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59, 4291-4296.
8. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
9. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357.
10. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L, et al. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104, 7564-7569.
11. Wu Z, Conaway M, Gioeli D, Weber MJ, and Theodorescu D (2006). Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 66, 1114-1123.
12. Oxford G, Smith SC, Hampton G, and Theodorescu D (2007). Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector. Oncogene 26, 7143-7152.
13. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, and Lee JK (2003). Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 19, 1945-1951.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, and Speed TP (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
15. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406.
16. Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, Ser B Stat Methodol 57, 289-300.
17. Vadigepalli R, Chakravarthula P, Zak DE, Schwaber JS, and Gonye GE (2003). PAINT: a promoter analysis and interaction network generation tool for gene regulatory network identification. OMICS 7, 235-252.
18. Mise-Omata S, Obata Y, Iwase S, Mise N, and Doi TS (2005). Transient strong reduction of PTEN expression by specific RNAi induces loss of adhesion of the cells. Biochem Biophys Res Commun 328, 1034-1042.
19. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR, and Williams RS (1998). Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 95, 3603-3608.
20. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22, 2790-2799.
21. 1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol 19, 612-622.
22. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR, McAvoy E, Robinson RG, Duggan ME, Lindsley CW, et al. (2005). Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4, 271-279.
23. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, et al. (2007). Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11, 555-569.
24. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98, 13681-13686.
25. Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, et al. (2001). Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci USA 98, 13138-13143.
26. Wu Z, McRoberts K, and Theodorescu D (2007). The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis 28, 1393-1400.
27. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, and Sawyers CL (2007). Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104, 5563-5568.
28. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, and Brown PO (2004). Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2, E7.
29. O'Shaughnessy JA (2006). Molecular signatures predict outcomes of breast cancer. N Engl J Med 355, 615-617.
30. Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, and Nakamura Y (2001). Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 61, 3741-3749.
31. Tiwari G, Sakaue H, Pollack JR, and Roth RA (2003). Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. Mol Cancer Res 1, 475-484.
32. Yao D, Alexander CL, Quinn JA, Porter MJ, Wu H, and Greenhalgh DA (2006). PTEN loss promotes rasHa-mediated papillomatogenesis via dual upregulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 66, 1302-1312.
33. Bartek J, Bartkova J, and Lukas J (1996). The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 8, 805-814.
34. Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, and Jorcano JL (1999). PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18, 7462-7468.
35. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, and Yin Y (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157-170.
36. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, and Li B (2007). Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 67, 976-988.
37. 1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95, 15406-15411.
38. Cook JG, Park CH, Burke TW, Leone G, DeGregori J, Engel A, and Nevins JR (2002). Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci USA 99, 1347-1352.
39. Steeg PS and Theodorescu D (2008). Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5, 206-219.
40. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, and Kunz M (2007). Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13, 806-815.
41. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, et al. (2006). Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12, 3319-3328.